These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2616267)

  • 21. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Audit of bone marrow aspirates and trephine biopsies in multiple myeloma--a single centre study.
    Charles KS; Winfield DA; Angel C; Goepel J
    Clin Lab Haematol; 2004 Dec; 26(6):403-6. PubMed ID: 15595998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of MRI for the diagnosis and prognosis of multiple myeloma.
    Baur-Melnyk A; Buhmann S; Dürr HR; Reiser M
    Eur J Radiol; 2005 Jul; 55(1):56-63. PubMed ID: 15950101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.
    Athanasiou E; Kaloutsi V; Kotoula V; Hytiroglou P; Kostopoulos I; Zervas C; Kalogiannidis P; Fassas A; Christakis JI; Papadimitriou CS
    Am J Clin Pathol; 2001 Oct; 116(4):535-42. PubMed ID: 11601138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The percentage of bone marrow plasmacytes and prognosis in multiple myeloma].
    Paule B; Quillard J; Bennet P; Bisson M; Massias P
    Rev Rhum Mal Osteoartic; 1988 Dec; 55(12):969-72. PubMed ID: 3238308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
    J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute plasmablastic leukemia in multiple myeloma].
    Solov'eva EA; Kruglova GV; Frenkel' MA; Drugush EK
    Ter Arkh; 1986; 58(9):36-40. PubMed ID: 3787488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The prognostic significance of cytological study of the bone marrow in multiple myeloma].
    Iakovleva SV
    Ter Arkh; 2000; 72(7):48-51. PubMed ID: 10983321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelomatous pleural effusion in a patient with plasmablastic myeloma: a case report.
    Chang H; Chou WC; Lee SY; Huang JY; Hung YH
    Diagn Cytopathol; 2009 Mar; 37(3):205-7. PubMed ID: 19170175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled environment culture of bone marrow explants from human myeloma.
    Gailani S; McLimans WF; Mundy GR; Nussbaum A; Roholt O; Zeigel R
    Cancer Res; 1976 Apr; 36(4):1299-304. PubMed ID: 4220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unusual evolution of Waldenström's macroglobulinemia into osteolytic myeloma.
    Jondeau K; Alterescu R; Franc B; Davi F; Massé JM; Boukour S; Le Parc JM; Cramer EM
    Eur J Haematol; 2006 Jul; 77(1):74-9. PubMed ID: 16827885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytopathological features of multiple myeloma].
    Takeuchi T; Adachi Y; Ikezoe T; Yokoyama A; Furihata M; Ohtsuki Y
    Nihon Rinsho; 2007 Dec; 65(12):2250-5. PubMed ID: 18069269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow plasma cell infiltration in multiple myeloma.
    de Gramont A; Benitez O; Smadja N; Brissaud P; Sirinelli A; Hubert D; Krulik M; Debray J
    Br J Haematol; 1984 Jun; 57(2):351-3. PubMed ID: 6733051
    [No Abstract]   [Full Text] [Related]  

  • 36. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Unusual presentation of plasma cell myeloma].
    Bürgesser MV; Basquiera AL; Diller A
    Medicina (B Aires); 2012; 72(3):251-4. PubMed ID: 22763165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
    Eladl E; Chang H
    Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296
    [No Abstract]   [Full Text] [Related]  

  • 40. CD31 expression in plasmacytic/plasmablastic lesions.
    Plocharczyk E; Wakely PE
    Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.